sCD30 Human ELISA

Summary

CD30 positivity is regarded as a peculiar attribute of Hodgkin's and Reed-Sternberg cells. High elevations of sCD30 levels are found in patients of systemic lupus erythematosus which correlate with disease activity. sCD30 is also a marker for autoimmune liver disease primary biliary cirrhosis and rheumatoid arthritis.

Research topic

Cell surface proteins (sCD), Oncology

Assay format

Sandwich ELISA, HRP-labelled antibody

Applications

Cell culture supernatant, Plasma-Citrate, Serum

Sample requirements

25 µl

Storage/Shipping

2–8°C

Calibration Curve

Calibration range

1.6 – 100 ng/ml

Limit of detection

0.33 ng/ml

Intra-assay

CV = 4.1%

Inter-assay

CV = 5.6%

Spiking Recovery

104%

Dilution Linearity

99%

References to summary

• Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science. 1994 Apr 29;264 (5159):667-8
• Caligaris-Cappio F, Bertero MT, Converso M, Stacchini A, Vinante F, Romagnani S, Pizzolo G. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol. 1995 May-Jun;13 (3):339-43
• Chilosi M, Facchetti F, Notarangelo LD, Romagnani S, Del Prete G, Almerigogna F, De Carli M, Pizzolo G. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Eur J Immunol. 1996 Feb;26 (2):329-34
• Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature. 1994 Feb 3;367 (6462):425-8
• Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992 Feb 7;68 (3):421-7
• Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995 Jan 1;85 (1):1-14
• Farrah T, Smith CA. Emerging cytokine family. Nature. 1992 Jul 2;358 (6381):26
• Fattovich G, Vinante F, Giustina G, Morosato L, Alberti A, Ruol A, Pizzolo G. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol. 1996 Jan;103 (1):105-10
• Fonatsch C, Latza U, Durkop H, Rieder H, Stein H. Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics. 1992 Nov;14 (3):825-6
• Froese P, Lemke H, Gerdes J, Havsteen B, Schwarting R, Hansen H, Stein H. Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J Immunol. 1987 Sep 15;139 (6):2081-7
• Gerli R, Muscat C, Bistoni O, Falini B, Tomassini C, Agea E, Tognellini R, Biagini P, Bertotto A. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol. 1995 Dec;102 (3):547-50
• Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994 Apr 15;83 (8):2045-56
• Hansen HP, Kisseleva T, Kobarg J, Horn-Lohrens O, Havsteen B, Lemke H. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer. 1995 Nov 27;63 (5):750-6
• Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol. 1989 Jan;19 (1):157-62
• Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM. Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol. 1996 Sep;80 (3 Pt 1):311-20
• Latza U, Foss HD, Durkop H, Eitelbach F, Dieckmann KP, Loy V, Unger M, Pizzolo G, Stein H. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol. 1995 Feb;146 (2):463-71
• Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol. 1994 Apr;12 (4):793-7
• Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol. 1994 Apr;12 (4):793-7
• Nadali G, Vinante F, Stein H, Todeschini G, Tecchio C, Morosato L, Chilosi M, Menestrina F, Kinney MC, Greer JP, et al. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol. 1995 Jun;13 (6):1355-60
• Nawrocki JF, Kirsten ES, Fisher RI. Biochemical and structural properties of a Hodgkin's disease-related membrane protein. J Immunol. 1988 Jul 15;141 (2):672-80
• Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982 Sep 2;299 (5878):65-7
• Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994 Mar 25;76 (6):959-62
• Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, Sutherland GR, Brannan CI, Copeland NG, Jenkins NA, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993 Jul 2;73 (7):1349-60
• Stein H, Gerdes J. [Phenotypic and genotypic marker in malignant lymphomas: cellular origin of Hodgkin's disease and malignant histiocytosis as well as implications for classifying T-cell and B-cell lymphomas]. Verh Dtsch Ges Pathol. 1986;70:127-51
• Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985 Oct;66 (4):848-58
• Vinante F, Morosato L, Siviero F, Nadali G, Rigo A, Veneri D, de Sabata D, Vincenzi C, Chilosi M, Semenzato G, et al. Soluble forms of p55-IL-2R alpha, CD8, and CD30 molecules as markers of lymphoid cell activation in infectious mononucleosis. Haematologica. 1994 Sep-Oct;79 (5):413-9

By research topic:

• Cell surface proteins (sCD)
• Oncology

By molecule:

• CD30

Registration form